They see it as a quicker path to treat infected patients while the global community awaits a vaccine, which scientists say could take between 12 and 18 months to develop, depending on the success of current trials.
The study published in the Journal of Virus Eradication 2020, titled"Minimum costs to manufacture new treatments for Covid-19", analyses the cost of production of several promising drugs - remdesivir, favipiravir, hydroxychloroquine, chloroquine, azithromycin, lopinavir/ritonavir, sofosbuvir/daclatasvir, and pirfenidone - currently in clinical trials globally with results expected to be known from May onwards.
“Estimations for the minimum production costs can strengthen price negotiations and help ensure affordable access to vital treatment for Covid-19 at low prices globally,” the journal reported. The minimum costs of drug production can be estimated by calculating the cost of active pharmaceutical ingredients , which is combined with costs of excipients, formulation, packaging and a profit margin, to estimate the price of"final finished product" .
For example, lopinavir/ritonavir retails for US$503 per course in the US. This study estimated its cost price at US$4 per course instead. Pirfenidone is being sold for US$9,606 per course , but the paper estimated its cost to be US$31. Jessica Burry, a pharmacist with MSF Access Campaign said this pricing study shows clearly that potential medicines to treat Covid-19 are not at all expensive to produce and could be priced such that anyone who needs treatment should be able to access it.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: staronline - 🏆 4. / 75 Read more »
Source: fmtoday - 🏆 5. / 72 Read more »
Source: staronline - 🏆 4. / 75 Read more »
Source: NST_Online - 🏆 17. / 53 Read more »
Source: malaymail - 🏆 1. / 86 Read more »
Source: malaysiakini - 🏆 20. / 51 Read more »